详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Advances in the Therapeutic Use of Non-ergot Dopamine Agonists in the Treatment of Motor and Non-motor Symptoms of Parkinson's Disease

1| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurology, TongRen Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [2]Center for Clinical Research on Neurological Diseases, the First Affiliated Hospital, Dalian Medical University, Dalian 116021, China. [3]Department of Neurology, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出处：

DOI：

ISSN：

摘要：

Dopamine (DA) agonists, as an excellent dopamine replacement therapy for patients with early and advanced Parkinson's disease (PD), play a vital role in controlling motor and several non-motor symptoms. Besides, the application of DA agonists may delay levodopa therapy and the associated risk of motor complications. Indeed, each DA agonist has unique pharmacokinetic and pharmacodynamic characteristics and therefore has different therapeutic efficacy and safety profile. The comorbidities, significant non-motor manifestations, concomitant medications, and clinical features of PD individuals should guide the selection of a specific DA agonist to provide a more patient-tailored treatment option. Thorough knowledge of DA agonists helps clinicians better balance clinical efficacy and side effects. Therefore, this review refers to recent English-written articles on DA agonist therapy for PD patients and summarizes the latest findings on non-ergot DA agonists as well as the advantages and disadvantages of each compound to help clinicians in the selection of a specific DA agonist. In addition, novel D1/D5 partial agonists and new formulations of DA agonists are also discussed.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版中科院分区表Review为是的期刊

：

大类 | 2 区医学

小类 | 2 区神经科学 2 区药学

最新[2025]版

：

大类 | 3 区医学

小类 | 2 区药学 3 区神经科学

JCR分区：

出版当年[2021]版：

Q1 NEUROSCIENCES Q1 PHARMACOLOGY & PHARMACY

最新[2024]版：

Q1 NEUROSCIENCES Q1 PHARMACOLOGY & PHARMACY

影响因子： 5.3 最新[2024版] 7.4 最新五年平均 7.708 出版当年[2021版] 9.589 出版当年五年平均 7.39 出版前一年[2020版] 5.3 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Neurology, TongRen Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

通讯作者：

通讯机构： [1]Department of Neurology, TongRen Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [3]Department of Neurology, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：